Publication date: Oct 06, 2019
The majority of patients with Parkinson disease develop Parkinson disease psychosis (PDPsy); however, pimavanserin may be an effective treatment option for patients, according to a recent study published by Neuropsychiatric Disease and Treatment. Researchers conducted a systematic review of randomized placebo-controlled trials comparing atypical antipsychotic with a placebo.
Databases, including PubMed, the Cochrane Library, ISI Web of Science, and Embase, were searched in order to find 13 randomized placebo-controlled trials with a total of 1142 cases involving pimavanserin, clozapine, olanzapine, and quetiapine. -Treatment of PDPsy may be difficult due to the modest efficacy of antipsychotics and the risk of worsening motor function.
-Recently, accessible antipsychotic drugs such as pimavanserin, clozapine, olanzapine, quetiapine have become of common use for the treatment of PDPsy.
|disease||MESH||adverse drug reactions|
- Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson’s disease.